stocksfeed.ai
← Back to news feed

LLY overview

LLY
Eli Lilly and Company
1,382.75
USD
-71.68 (-4.93%)since Nov 16, 2026

News about LLY

6 stories shown

LLYproduct launch

Health Canada has approved Eli Lilly's Mounjaro to lower cardiovascular risk in patients with type 2 diabetes and heart disease.

Seeking Alpha
View original
RYTMLLYmerger acquisition

Rhythm Pharmaceuticals shares rose 3.6% following reports that Eli Lilly submitted a rival acquisition bid.

Seeking Alpha
View original
LLYmerger acquisition

Eli Lilly entered into a multibillion-dollar collaboration with Stipple Bio and agreed to acquire Calytrix Bio to expand its oncology portfolio.

Benzinga
View original
LLYproduct launch

Eli Lilly's Zepbound trial showed promising weight loss results in adolescents, though approval for younger patients remains uncertain.

Seeking Alpha
View original
LLYMRKanalyst commentary

Analysts identify Eli Lilly, Roche, and Merck as attractive Big Pharma stocks, driven by raised guidance and long-term recovery prospects.

Seeking Alpha
View original
LLYproduct launch

China has approved Eli Lilly's GLP-1 weight-loss pill, granting the company a lead over competitor Novo Nordisk.

Seeking Alpha
View original